CIK 0001709941 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
BioAge Labs, Inc.
Sign in to watch- Ticker
- BIOA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 474721157
- Phone
- 510-806-1445
- Business address
- 5885 HOLLIS STREET, SUITE 370, EMERYVILLE, CA, 94608
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-30 | Barton Shane Principal Accounting Officer | Option exercise 10b5-1 | +4,290 | $10.85 | $47K | 4,290 |
| 2026-06-30 | Barton Shane Principal Accounting Officer | Option exercise 10b5-1 | +4,000 | $8.39 | $34K | 8,290 |
| 2026-06-30 | Barton Shane Principal Accounting Officer | Option exercise 10b5-1 | +4,065 | $4.30 | $17K | 12,355 |
| 2026-06-30 | Barton Shane Principal Accounting Officer | Option exercise 10b5-1 | +7,861 | $4.38 | $34K | 20,216 |
| 2026-06-30 | Barton Shane Principal Accounting Officer | Sale 10b5-1 | −20,216 | $25.19 | $509K | 0 |
| 2026-06-30 | Barton Shane Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,290 | 13,299 | ||
| 2026-06-30 | Barton Shane Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,000 | 17,016 | ||
| 2026-06-30 | Barton Shane Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,065 | 26,977 | ||
| 2026-06-30 | Barton Shane Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,861 | 67,941 | ||
| 2026-06-29 | Barton Shane Principal Accounting Officer | Option exercise 10b5-1 | +9,301 | $10.85 | $101K | 11,933 |
| 2026-06-29 | Barton Shane Principal Accounting Officer | Option exercise 10b5-1 | +7,261 | $8.39 | $61K | 19,194 |
| 2026-06-29 | Barton Shane Principal Accounting Officer | Option exercise 10b5-1 | +8,958 | $4.30 | $39K | 28,152 |
| 2026-06-29 | Barton Shane Principal Accounting Officer | Option exercise 10b5-1 | +14,198 | $4.38 | $62K | 42,350 |
| 2026-06-29 | Barton Shane Principal Accounting Officer | Sale 10b5-1 | −42,350 | $25.21 | $1.1M | 0 |
| 2026-06-29 | Barton Shane Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,301 | 17,589 | ||
| 2026-06-29 | Barton Shane Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,261 | 21,016 | ||
| 2026-06-29 | Barton Shane Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,958 | 31,042 | ||
| 2026-06-29 | Barton Shane Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −14,198 | 75,802 | ||
| 2026-06-10 | Pande Vijay Satyanand Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2026-06-10 | Hemrajani Rekha Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 |
Page 1 of 7 · 124 trades